⚠️ Neutral
Listed
Healthcare Services
Molbio Diagnostics Limited IPO
₹940 Cr · Fresh Issue & OFS · Healthcare Services
Price Band
₹768 – ₹807
GMP (Grey Market)
—
No GMP data yet
Issue Size
₹940 Cr
Fresh Issue & OFS
Market Cap
₹9299.87 Cr
At upper band
P/E Ratio
56.7x
P/S: 6.4x
Listing Date
17 Aug 2026
BSE & NSE
IPO Timeline
✓
Opens
10 Aug 2026
✓
Closes
12 Aug 2026
✓
Allotment
13 Aug 2026
✓
Refund
14 Aug 2026
✓
Listing
17 Aug 2026
IPO India Hub: Neutral
Conviction
5/10
The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and declining promoter ownership post-issue create offsetting concerns that warrant caution despite solid operational metrics.
Listing Performance
Issue Price
₹807
Allotment price
Listing Price
₹980
+21.44% on listing day
Current Price (CMP)
₹1312.2
+62.6% vs issue
Listed On
17 Aug 2026
BSE & NSE
Our Analysis — Key Points
✓ Strength
Exceptional profit growth trajectory
Net profit has grown 40.2% over two years (₹83.5 Cr to ₹164.1 Cr), significantly outpacing revenue growth of 31.6%, indicating strong operational leverage and margin expansion. EBITDA margin of 24.97% and ROCE of 20.98% demonstrate efficient capital deployment and pricing power in diagnostics.
✓ Strength
Consistent revenue acceleration
Revenue grew from ₹840.7 Cr (FY-2) to ₹1,455.2 Cr (FY0), reflecting sustained market demand and likely geographic or service expansion. The 31.6% two-year CAGR places the company in the upper quartile of healthcare services growth in India.
⚠ Risk
Massive OFS dilutes fresh capital benefit
78.7% of the ₹940 Cr issue is OFS (secondary sale), meaning only ~₹200 Cr flows to the company for capex and growth. This severely limits the IPO's value to the business and raises questions about why promoters are exiting at this valuation.
⚠ Risk
Promoter stake erosion post-listing
Promoter holding drops from 44.89% pre-issue to 41.29% post-issue, signaling dilution and reduced alignment with minority shareholders. Combined with 78.7% OFS, this suggests promoters may be taking profits rather than investing in growth.
₹ Valuation
Fair valuation offset by margin concerns
P/E of 56.7× translates to 1.42× the sector midpoint of 40×, placing it within the Subscribe threshold for healthcare diagnostics. However, NPM of 11.4% falls well below the 15% threshold that would justify premium valuation, and P/S of 6.4× is elevated for the sector.
👁 Watch
Monitor capex deployment and margin sustainability
Track whether the limited fresh capital (₹200 Cr) is deployed efficiently into R&D and infrastructure as stated, and whether the 24.97% EBITDA margin can be sustained as the company scales post-listing.
Top Analyst Reviews
| Analyst / Firm | Rating | Known For | Review |
|---|---|---|---|
| IPO India Hub Our independent review |
Original analysis based on DRHP & public financials | This page | |
| Dilip Davda Chittorgarh.com |
India's most followed independent IPO analyst | Search on Chittorgarh → | |
| Capital Market (CM Rating) CapitalMarket.com |
Widely-cited "New Issue Monitor" reports | Search on CapitalMarket → | |
| ICICI Securities ICICIdirect Research |
SEBI-registered broker research desk | Visit ICICIdirect → | |
| IPO Guru Analyst Leaderboard ipoguru.in |
Ranks 49 analysts by real IPO outcome accuracy | View leaderboard → |
External links go to each platform's IPO section — search for "Molbio Diagnostics Limited" to find the specific review. IPO India Hub does not represent the accuracy of third-party ratings.
Company Snapshot
Revenue
₹1445.69 Cr
Net Profit
₹164.14 Cr
Industry
Healthcare Services
Issue Type
Fresh Issue & OFS
Promoters
SRIRAM NATARAJAN, DR. CHANDRASEKHAR BHASKARAN NAIR, SANGEETHA SRIRAM, SHIVA SRIRAM, SOWMYA SRIRAM AND EXXORA TRADING LLP
Lead Managers
Kotak Mahindra Capital, IIFL Capital, Jefferies and Motilal Oswal Investment Advisory
Quick Actions
Frequently Asked Questions
Neutral. The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and declining promoter ownership post-issue create offsetting concerns that warrant caution despite solid operational metrics.
GMP data is not yet available for this IPO. Check our GMP Live page for the latest updates closer to the listing date.
Lot size details will be updated when the DRHP is filed. The price band is ₹768 – ₹807.
The IPO opens on 10 Aug 2026. It closes on 12 Aug 2026. Allotment is expected on 13 Aug 2026. Refunds initiate on 14 Aug 2026. Listing on BSE and NSE is on 17 Aug 2026.
The lead managers for the IPO are Kotak Mahindra Capital, IIFL Capital, Jefferies and Motilal Oswal Investment Advisory. Check the SEBI filing for the registrar details.
The IPO listed on 17 Aug 2026 at ₹980 against an issue price of ₹807 (+21.44% on listing day). The current market price (CMP) is approximately ₹1312.2 (+62.6% vs issue).
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 12 Aug 2026. The company shows strong revenue growth (31.6% CAGR) and exceptional PAT expansion (40.2% CAGR), but valuation at 1.42× sector midpoint combined with a 78.7% OFS component and declining promoter ownership post-issue create offsetting concerns that warrant caution despite solid operational metrics.
Our analysis is <strong>Neutral</strong>. Consider applying selectively before the issue closes on 12 Aug 2026. The IPO is priced at a P/E of 56.7x. Market cap at issue price is ₹9299.87 Cr. As with all IPOs, please read the DRHP and assess your own risk tolerance before investing.
You can apply via UPI through your broker's trading app (Zerodha, Upstox, Fyers, etc.) or via ASBA through your net banking portal. The issue closes on 12 Aug 2026, so apply before that date. Step 1: Log in to your broker or bank app. Step 2: Go to IPO section and search for 'Molbio Diagnostics Limited'. Step 3: Enter the number of lots and UPI ID. Step 4: Accept the mandate on your UPI app.
Explore More